Longitudinal Economic Burden for Non–Muscle-Invasive Bladder Cancer by EAU Progression Risk Groups Using the Prospective Multicenter COBLAnCE Cohort Linked to the French National Healthcare System Database
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: Data on longitudinal bladder cancer (BC) costs are scarce. Objective: To assess the economic burden of non-muscle-invasive bladder cancer (NMIBC) by progression risk groups in France over a 1-yr and 5-yr time horizon after initial diagnosis. Design setting and participants: We used data from the French national prospective COhort to study BLAdder CancEr (COBLAnCE) cohort. A total of 1101 patients diagnosed with a primary NMIBC between 2012 and 2018 were linked with the French National Healthcare System Database. Patients were classified into four risk groups according to the 2021 European Association of Urology risk stratification. Resources used included all BC-related hospitalizations, follow-up visits to urology and oncology clinics and related prescriptions, BC-related imaging procedures, transportation, and sick leaves. Costs were estimated from the perspective of the French health care system over the 5 yr after BC diagnosis. Outcome measurements and statistical analysis: Across risk groups, mean per-patient cost ranged from €5838 to €20 678 and €11 697 to €40 519 over 1 yr and 5 yr, respectively. Surgical hospital stays accounted for 60% of costs in the first year. Over 5 yr, intravesical treatments, surveillance visits, and imaging were major cost drivers, especially among patients at lower risk of progression. Results and limitations: Although claims databases are comprehensive, the economic burden of NMIBC may be underestimated owing to potential incomplete coding. Conclusions: To our knowledge, this is the first national cohort study to provide robust cost estimates for patients with NMIBC stratified according to progression risk groups. These real-world data are particularly awaited for the economic evaluation of emerging treatments in patients with NMIBC.
Source: European Urology Open Science
Authors: Aldéric M. Fraslin, Simone Benhamou, Thierry Lebret, Yann Neuzillet, Stéphane Droupy, Grégoire Poinas, Dimitri Vordos, Laurent Guy, Gautier Marcq, Marc Schneider, Patrick Coloby, Arnaud Monges, Arnaud Méjean, Eric Potiron, Jean-Luc Descotes, Pascal Eschwege, Guillaume Loison, Clémentine Krucker, Anthony Mangin, François Radvanyi, Yves Allory, Maryam Karimi, Julia Bonastre
Institutions: Inserm, Université Paris-Saclay, Institut Gustave Roussy, Université de Versailles Saint-Quentin-en-Yvelines, Hôpital Foch, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, Centre Hospitalier Universitaire de Clermont-Ferrand, Centre National de la Recherche Scientifique, Université de Lille, Institut Pasteur de Lille, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, CANTHER - Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers, Hôpital NOVO, Hôpital Européen Georges-Pompidou, Centre Hospitalier Universitaire de Grenoble, Hôpital Albert Michallon, Centre Hospitalier Régional et Universitaire de Nancy, CRAN, Imagerie, Radiothérapie Innovante et médecine des Systèmes, Institut Curie, Biologie cellulaire et Cancer
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: gold
Estimated APC paid: $1,800
Funder: Institut National Du Cancer
Award: G69398484
OpenAlex ID: W7208772926